stockrow
Friday 6 November 2026
Export BHVN’s income statement to Excel — free account
Biohaven Ltd.
BHVN Healthcare Biotechnology
- EPS
- +47.8%
- Free cash flow
- +26.6%
- Total debt
- −1.48%
Quarter to September 2026, against a year earlier
14.41
0.51
+3.67%
Follow BHVN
Alert me
Biohaven Ltd. (BHVN) Net margin
Biohaven Ltd.'s net margin over the twelve months to 30 September 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from 0.00% (fiscal 2025) to 0.00% (fiscal 2025) — the current reading is the highest in ten years. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Net margin, annual
Embed this chart
Annual newest first
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | 0.00 |
| FY2017 | 0.00% | 0.00 |
| FY2016 | 0.00% | 0.00 |
Quarterly newest first
| Period | Net margin | Change (points) |
|---|---|---|
| Sep 2026 | 0.00% | 0.00 |
| Jun 2026 | 0.00% | 0.00 |
| Mar 2026 | 0.00% | 0.00 |
| Dec 2025 | 0.00% | 0.00 |
| 39 more quarters | Free account |
Against its own ten years
Low 0.00%
High 0.00%
Ten-year median
0.00%
Current reading's percentile
100
Net margin against peers
| Company | Net margin |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | 97.7% |
| ADMA ADMA Biologics Inc compare | 35.1% |
| VCEL Vericel Corporation compare | 10.3% |
| IMNM Immunome, Inc. compare | 0.00% |
| VERA Vera Therapeutics, Inc. compare | 0.00% |
| BHVN Biohaven Ltd. | 0.00% |
| PVLA Palvella Therapeutics, Inc. compare | 0.00% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −6.81% |
| CLDX Celldex Therapeutics, Inc. compare | −33,883.8% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 1.06% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue